Tuesday - May 6, 2025
HENDERSON, Nev. / Jan 30, 2024 / Business Wire / P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Management is scheduled to host investor meetings on Tuesday, February 13th, and Wednesday February 14th, 2024.
About P3 Health Partners (NASDAQ: PIII)
P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,700 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. For more information, visit www.p3hp.org and follow us on LinkedIn and Facebook.com/p3healthpartners.
Last Trade: | US$8.65 |
Daily Change: | -0.14 -1.59 |
Daily Volume: | 592 |
Market Cap: | US$1.410B |
November 27, 2024 November 12, 2024 October 17, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load